The study involves people with liver cirrhosis who need a procedure called large-volume paracentesis to remove excess fluid from the abdomen. During this procedure, participants will receive an intravenous infusion of human serum albumin, a protein that helps keep fluid in the blood vessels. The trial compares the usual dose of albumin (8 g/L) with a lower dose (4 g/L) to determine whether the reduced amount can prevent serious liver‑related problems as effectively as the standard amount. The purpose of the study is to see if a lower dose of the albumin infusion works as well as the standard dose in preventing liver‑related complications.
Participants are randomly assigned to receive either the lower or the standard dose of the albumin infusion at the time of the fluid‑removal procedure and are then followed for up to one year. During this period, they will have regular clinic visits where blood tests and simple questionnaires are used to check for any new health issues, such as infections of the abdominal fluid (spontaneous bacterial peritonitis), kidney problems caused by liver disease (hepatorenal syndrome – acute kidney injury), bleeding from enlarged veins in the esophagus (variceal bleeding), or changes in brain function due to liver failure (hepatic encephalopathy). The study also records overall well‑being and any hospital visits, but no technical details of the measurements are provided.
The Netherlands 
